Miniatura

Fitxers

654364.pdf (1.41 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2015-10-02

Llicència de publicació

cc-by (c) Diaz Beya, Marina et al., 2015
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/127424

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1038/bcj.2015.76

Resum

Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.

Matèries

Leucèmia mieloide, Pronòstic mèdic, Malalts de càncer, Micro RNAs

Matèries (anglès)

Myeloid leukemia, Prognosis, Cancer patients, MicroRNAs

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

DÍAZ BEYÀ, Marina, BRUNET, Salut, NOMDEDÉU GUINOT, Josep francesc, CORDEIRO SANTANACH, Anna, TORMO, Mar, ESCODA, Lourdes, RIBERA, Josep maria, HERAS, Inmaculada, GALLARDO GIRALT, David, BARGAY, Joan, QUEIPO DE LLANO, María paz, SALAMERO, Olga, MARTÍ, Josep maría, SAMPOL, Antonia, PEDRO, Carme, HOYOS COLELL, Montserrat, PRATCORONA, Marta, CASTELLANO, Joan josep, NOMDEDEU I FÀBREGA, Meritxell, RISUEÑO, Ruth m., SIERRA GIL, Jorge, MONZÓ PLANELLA, Mariano, NAVARRO PONZ, Alfons, ESTEVE REYNER, Jordi, ARNAN, Montserrat. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. _Blood Cancer Journal_. 2015. Vol. 5, núm. e352. [consulta: 24 de gener de 2026]. ISSN: 2044-5385. [Disponible a: https://hdl.handle.net/2445/127424]

Exportar metadades

JSON - METS

Compartir registre